Catalent Inc Stock News

Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.

May was only a so-so month for most S&P 500 investors. But some investors who hit the tech-stock boom just right this month did really well.

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.

The specialty healthcare company gets another piece of bad news. But this was comparatively mild when judged against other recent developments.

U.S. equities declined on Friday, May 19, 2023 as GOP negotiators called for a pause in talks to raise the federal debt ceiling.

Catalent shares jumped after the contract drug maker said customer supplies are strong and it's getting "significant" new business.

Struggling biotechnology specialist Catalent (NYSE: CTLT ) popped significantly higher on Friday despite poor financial performances and prognostications. Nevertheless, management helped soothe nerves

Shares of Catalent (CTLT) are surging on Friday after the contract pharmaceuticals manufacturer provided an update on its full-year outlook and past-due financials. Catalent stock is up over 17% in

Yahoo Finance markets contributor Remy Blaire breaks down the morning market action while also taking a look at shares of Foot Locker and Catalent.

Catalent, Inc. (NYSE:CTLT ) Q3 2023 Business Update Transcript May 19, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President & Chief Exec

Catalent trimmed its annual revenue and net income forecasts. The contract drug manufacturer said the cuts were due to operational challenges.

Catalent Inc cut its full-year net revenue forecast on Friday, reflecting operational challenges and higher-than-expected costs after it flagged an over $400 million hit to both its annual sales and c

Shares of Catalent Inc. CTLT, +0.06% sank 5.2% toward a 4 1/2-year low in premarket trading Friday, after the manufacturer of products used by drug makers and consumer health companies cut its full-ye

Shares of Catalent Inc. CTLT, +0.06% dove to a 5.9% loss in premarket trading Friday, after the provider of delivery technologies and manufacturing services for drug makers said it has received notice

Earnings season has been better than feared, and we highlight two firms offering differing views on the state of the economy. There's also one falling Pharma company that (once again) delayed its Q3 r